Steven A. Kaplan

Steven A. Kaplan

Auto-generated profile, based on publicly available information

Steven A. Kaplan

Icahn School of Medicine at Mount Sinai, New York, New York

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2006 in JAMA
Verified
Journal Article
Open access
PDF file
SKSteven A. Kaplan
Steven A. Kaplan
CRClaus G. Roehrborn
Claus G. Roehrborn
EREric S. Rovner
Eric S. Rovner
MCMartin Carlsson
Martin Carlsson
TBTamara Bavendam
Tamara Bavendam
ZGZhonghong Guan
Zhonghong Guan
Overactive bladder is a syndrome characterized by urinary urgency, with or without urgency urinary incontinence, usually with increased micturition frequency during the day and at night (ie, nocturia).1 An estimated 10 million men 40 years or older have symptoms consistent with overactive bladder.2 Overactive bladder symptoms are often attributed to detrusor overactivity, a condition characterized by involuntary detrusor contractions during bladder filling.1

17 January 2007 in European Urology
Verified
Journal Article
Closed access
PDF file
SKSteven A. Kaplan
Steven A. Kaplan
RGRicardo R. Gonzalez
Ricardo R. Gonzalez
ATAlexis E. Te
Alexis E. Te

1 October 2006 in Journal of Urology
Verified
Journal Article
Closed access
SKSteven A. Kaplan
Steven A. Kaplan
AMAlan G. Meehan
Alan G. Meehan
ASArvind Shah
Arvind Shah
We examined pooled baseline data from 2 lipid treatment studies to evaluate the relationship among total serum testosterone levels, obesity and the metabolic syndrome in aging men. Baseline total serum testosterone, lipid, glycemic and anthropometric data were obtained from 864 men (mean age 52 years) participating in 2 lipid treatment studies. Inclusion criteria for the 2 studies included low-density lipoprotein cholesterol 130 to 160 mg/dl and triglycerides 350 mg/dl or less. For all patients as well as the nonmetabolic syndrome and the metabolic syndrome cohorts, testosterone decreased with increasing body mass index (p < 0.0001 for Pearson correlation coefficient in all 3 cohorts). Mean baseline total serum testosterone levels in obese and severely obese aging men with the metabolic syndrome were around 150 and 300 ng/dl, respectively, less than that in aging, lean men with no metabolic syndrome. The relative contributions of each of the individual National Cholesterol Education Program Adult Treatment Panel III components of the metabolic syndrome to low serum testosterone in aging men was examined using multiple linear regression modeling. Based on these analyses the presence of diabetes or fasting serum glucose greater than 110 mg/dl, body mass index 30 kg/m or greater, and triglycerides 150 mg/dl or greater each appeared to have a clinically relevant association with low serum testosterone. This study demonstrated that aging men with obesity and the metabolic syndrome have a significant decrease in total serum testosterone levels compared to aging, metabolically healthy men. These data suggest that the well established association between erectile dysfunction and pre-diabetes/diabetes (particularly in obese pre-diabetic/diabetic patients) may involve a hormonal component.

1 July 2008 in Journal of Urology
Verified
Journal Article
Closed access
SKSteven A. Kaplan
Steven A. Kaplan
AWAlan J. Wein
Alan J. Wein
DSDavid R. Staskin
David R. Staskin
CRClaus G. Roehrborn
Claus G. Roehrborn
WSWilliam D. Steers
William D. Steers
The definitions of acute and chronic urinary retention remain empirical and subject to wide interpretation. Standardized criteria have not been established and many questions remain unanswered. Moreover, the definition of significant post-void residual urine is unclear. We reviewed several aspects of urinary retention that require clarification with the objective of stimulating discussion among urologists to establish an accurate and coherent definition of urinary retention and significant post-void residual urine, and clarify risk factors. A MEDLINE search for articles written in English and published before April 2007 was done using a list of terms related to urinary retention. Articles not directly relevant to urinary retention or post-void residual urine were excluded. The term urinary retention lacks precise clinical or urodynamic meaning. Use of this term to describe a symptom, a sign, and a condition further complicates the issue. Many factors can contribute to the development of retention, including bladder outlet obstruction, detrusor underactivity, and neurogenic bladder conditions. Community based studies and clinical trials in patients with benign prostatic enlargement and/or lower urinary tract symptoms yield different estimates of the incidence of retention and only provide information on the epidemiology of acute urinary retention. However, age, previous retention episodes, lower urinary tract symptoms, chronic inflammation, serum prostate specific antigen level, prostate size, and urodynamic variables appear to be predictors of acute urinary retention. Alpha-receptor antagonists and 5alpha-reductase inhibitors may be useful in preventing urinary retention episodes and progressive benign prostatic enlargement. Clinical trials on the short-term use of antimuscarinics have not provided evidence that these agents increase the risk of retention; data on longer term administration are needed. Clinicians are adopting less invasive approaches (eg pharmacology or catheterization) to treating patients who present with the symptoms, sign, and condition of urinary retention. Faced with an abundance of new data on acute urinary retention, urologists need to reach a consensus about the risks of urinary retention; this may promote movement toward patient centered prevention strategies with tailored treatment options.

1 December 2005 in Journal of Urology
Verified
Journal Article
Closed access
PDF file
SKSteven A. Kaplan
Steven A. Kaplan
KWKonstantin Walmsley
Konstantin Walmsley
ATAlexis E. Te
Alexis E. Te
In this open label, prospective study we determined the efficacy and tolerability of tolterodine extended release (ER) in men with benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) in whom previous α-blocker therapy had failed. A total of 43 consecutive men with BPH and LUTS in whom a mean of 5.7 months of α-blocker therapy had failed due to adverse events (11) or a lack of efficacy (32) received tolterodine ER (4 mg daily) for 6 months. Primary efficacy end points were American Urological Association symptom score, and mean daytime and nighttime micturition frequency. Secondary end points were the peak urinary flow rate, post-void residual volume, the incidence of urinary retention, total score on the erectile function domain of the International Index of Erectile Function and adverse events. A total of 39 men (91%) with a mean age of 61 years completed the 6-month trial. Mean 24-hour micturition frequency decreased from 9.8 to 6.3 voids and nocturia decreased from 4.1 to 2.9 episodes nightly. Significant changes in mean American Urological Association symptom scores (–6.1), the peak urinary flow rate (1.9 ml per second) and post-void residual volume (–22 ml) were also observed. Of the men 27 (63%) were potent at baseline and 29 (67%) were potent after 6 months of tolterodine ER treatment. Mean International Index of Erectile Function erectile function domain scores increased (6.9). Four men (9%) discontinued therapy because of intolerable dry mouth. There were no reports of urinary retention. Treatment with tolterodine ER in men with BPH and LUTS may be a reasonable therapeutic option as initial therapy or after failed treatment with α-blockers.

13 January 2012 in BJU International
Verified
Journal Article
Closed access
PDF file
RLRichard K. Lee
Richard K. Lee
DCDoreen Chung
Doreen Chung
BCBilal Chughtai
Bilal Chughtai
ATAlexis E. Te
Alexis E. Te
SKSteven A. Kaplan
Steven A. Kaplan